Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William R Hiatt

Showing results (11-20 of 232) with videos related to

Pageof 24
Sort By:
Current Drug Targets. Cardiovascular & Haematological Disorders|September 24, 2004
Treatment of disability in peripheral arterial disease: new drugsWilliam R Hiatt
Atherosclerosis. Supplements|November 9, 2005
The US experience with cilostazol in treating intermittent claudicationWilliam R Hiatt
Journal of Vascular Surgery|December 7, 2002
Pharmacologic therapy for peripheral arterial disease and claudicationWilliam R Hiatt
Vascular Medicine (London, England)|March 24, 2020
From the Masters: A sea-change for TransAtlantic Inter-Society Consensus (TASC)William R Hiatt
Postgraduate Medicine|July 31, 2009
The burden of peripheral artery disease and the role of antiplatelet therapyHerbert Aronow, William R Hiatt
Vascular Medicine (London, England)|December 1, 2007
Why TASC II?Lars Norgren, William R Hiatt
Journal of Clinical Pharmacology|September 13, 2011
Improving the FDA's advisory committee processEric P Brass, William R Hiatt
Clinical and Translational Science|May 7, 2010
The FDA regulatory process for drug and genetic diagnostic test approvalsMichael R Bristow, William R Hiatt
Circulation|March 15, 2006
New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation: report from the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration, November 16, 2005, Rockville, MdWilliam R Hiatt, Steven E Nissen,
Circulation|March 21, 2018
Response by Brass and Hiatt to Letter Regarding Article, "Aspirin Monotherapy Should Not Be Recommended for Cardioprotection in Patients With Symptomatic Peripheral Artery Disease"Eric P Brass, William R Hiatt
Pageof 24

Showing results (11-20 of 232) with videos related to

Sort By:
Pageof 24
Current Drug Targets. Cardiovascular & Haematological Disorders|September 24, 2004
Treatment of disability in peripheral arterial disease: new drugsWilliam R Hiatt
Atherosclerosis. Supplements|November 9, 2005
The US experience with cilostazol in treating intermittent claudicationWilliam R Hiatt
Journal of Vascular Surgery|December 7, 2002
Pharmacologic therapy for peripheral arterial disease and claudicationWilliam R Hiatt
Vascular Medicine (London, England)|March 24, 2020
From the Masters: A sea-change for TransAtlantic Inter-Society Consensus (TASC)William R Hiatt
Postgraduate Medicine|July 31, 2009
The burden of peripheral artery disease and the role of antiplatelet therapyHerbert Aronow, William R Hiatt
Vascular Medicine (London, England)|December 1, 2007
Why TASC II?Lars Norgren, William R Hiatt
Journal of Clinical Pharmacology|September 13, 2011
Improving the FDA's advisory committee processEric P Brass, William R Hiatt
Clinical and Translational Science|May 7, 2010
The FDA regulatory process for drug and genetic diagnostic test approvalsMichael R Bristow, William R Hiatt
Circulation|March 15, 2006
New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation: report from the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration, November 16, 2005, Rockville, MdWilliam R Hiatt, Steven E Nissen,
Circulation|March 21, 2018
Response by Brass and Hiatt to Letter Regarding Article, "Aspirin Monotherapy Should Not Be Recommended for Cardioprotection in Patients With Symptomatic Peripheral Artery Disease"Eric P Brass, William R Hiatt
Pageof 24